PriceTargets.com logo

Akers Biosciences - AKER Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.56 As of 04/23/2024 01:00 AM ET
▼ -0.02 (-0.78%)
Get New Akers Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AKER and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AKER

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Akers Biosciences in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $2.56.

This chart shows the closing price for AKER for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Akers Biosciences. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/1/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/17/2022Berenberg BankDowngradeHold ➝ SellN/A
1/3/2022UBS GroupDowngradeBuy ➝ SellN/A
(Data available from 4/24/2019 forward)

News Sentiment Rating

-0.20 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 70 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
Mentions as of
9/27/2023
  • 3 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2023
  • 1 very positive mentions
  • 12 positive mentions
  • 5 negative mentions
  • 8 very negative mentions
Mentions as of
11/26/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2023
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
3/25/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Akers Biosciences logo
Akers Biosciences, Inc. focuses on the development of a vaccine candidate against SARS-CoV-2, a coronavirus causing a pandemic. It has a collaboration agreement with Premas Biotech PVT Ltd. The company was incorporated in 1989 and is headquartered in New York, New York.
Read More

Today's Range

Now: $2.56
Low: $2.55
High: $2.60

50 Day Range

MA: $3.56
Low: $2.47
High: $4.59

52 Week Range

Now: $2.56
Low: $1.65
High: $6.97

Volume

22,727 shs

Average Volume

769,876 shs

Market Capitalization

$42.63 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.3

Frequently Asked Questions

What sell-side analysts currently cover shares of Akers Biosciences?

The following sell-side analysts have issued research reports on Akers Biosciences in the last year:
View the latest analyst ratings for AKER.

What is the current price target for Akers Biosciences?

0 Wall Street analysts have set twelve-month price targets for Akers Biosciences in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Akers Biosciences in the next year.
View the latest price targets for AKER.

What is the current consensus analyst rating for Akers Biosciences?

Akers Biosciences currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for AKER.

What other companies compete with Akers Biosciences?

Other companies that are similar to Akers Biosciences include Aspira Women's Health, ImmuCell, ARCA biopharma, OncoCyte and Cardio Diagnostics. Learn More about companies similar to Akers Biosciences.

How do I contact Akers Biosciences' investor relations team?

Akers Biosciences' physical mailing address is 201 GROVE RD, THOROFARE NJ, 08086. The medical instruments supplier's listed phone number is 856 848 8698 and its investor relations email address is [email protected]. The official website for Akers Biosciences is www.akersbio.com. Learn More about contacing Akers Biosciences investor relations.